+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a limited duration treatment combining acalabrutinib and venetoclax in patients with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have relapsed after initially responding to first-line therapy with covalent BTKi and BCL2i drugs, with or without obinutuzumab. The study focuses on participants who maintained at least a partial remission for two years following their first treatment. Participants will receive a lead-in phase of two cycles of acalabrutinib, followed by either 12 or 22 cycles of the combined acalabrutinib and venetoclax treatment, depending on assigned risk cohort based on disease markers IGHV mutation and TP53 status. The total study duration for each participant is approximately five years, which includes up to four years of follow-up after treatment completion. During the study, participants will undergo regular assessments to measure the overall response rate at multiple time points during treatment cycles and annually thereafter. Additional evaluations include progression-free survival, duration of response, event-free survival, time to next treatment, overall survival, and rates of undetectable minimal residual disease. Safety and tolerability of the second-line treatment will be monitored throughout the five-year period. Participants will have visits and tests according to this schedule to track treatment effects and disease status.

Age: 18Years - 130YearsAll GendersPhase 2
47 locations